Log in to your Inderes Free account to see all free content on this page.
Isofol Medical
0.683 SEK +3.8%2 investors are following this company
Isofol Medical is a biotechnology company. The company conducts research and development in the fields of oncology. The company develops cancer drugs and drug candidates that are primarily intended for the treatment of colorectal cancer (CRC), one of the most common forms of cancer. In addition to the main activities, the companies also develop so-called rescue treatment after high-dose treatment with the cytotoxic methotrexate in osteosarcoma (bone cancer).
Revenue
720K
EBIT %
-5,788.89 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ISOFOL
Daily low / high price
0.66 / 0.7
SEK
Market cap
110.32M SEK
Turnover
23.01K SEK
Volume
33K
Latest videos
Financial calendar
Interim report
21.08.2024
Interim report
12.11.2024
Annual report
19.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 10.1 % | 10.1 % |
Christian Haglund | 4.7 % | 4.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Isofol Medical AB (publ) publishes interim report, January–March 2024
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio